Ovarian function in ewes after treatment with mifepristone early during the oestrous cycle.
The aim of this study was to determine whether endogenous progesterone regulates synthesis and secretion of luteal oxytocin. In Expt 1, mature ewes (n = 5 per group) were assigned randomly to control or mifepristone (RU486) treatment groups. Ewes were injected s.c. twice a day with vehicle or 10 mg RU486 on days 5-7 of the oestrous cycle (oestrus = day 0). On day 8, after an i.v. injection with prostaglandin F(2alpha) (250 microg cloprostenol), venous blood samples were collected at frequent intervals to determine plasma oxytocin concentrations. Plasma oxytocin concentrations of RU486-treated ewes were not significantly different from those of control ewes. In Expt 2, ewes were injected s.c. each day with vehicle or 175 mg RU486 on days 2-5 of the oestrous cycle followed by administration of prostaglandin F(2alpha) on day 6. Four of five RU486-treated ewes showed 'split-oestrus' (oestrous behaviour for 36 h and then again at 84-108 h after the onset of initial oestrus). There was no significant difference in mean plasma oxytocin or progesterone concentrations between treatment groups. The mean masses of mature corpora lutea from control and RU486-treated ewes on day 6 of the oestrous cycle did not differ significantly (394.8 +/- 28.8 versus 319.5 +/- 48.3 mg). RU486-treated ewes contained mature corpora lutea, new corpora lutea (two of four ewes) and preovulatory follicles (>or= 10 mm, two of four ewes). The average interoestrous interval for RU486-treated ewes was 9 days more than that for control animals (26.2 +/- 2.9 versus 17 +/- 0.5 days; P < 0.025).
Paslay
E M
EM
Department of Animal Sciences, Oregon State University, Corvallis, OR 97331-6702, USA.
Jaeger
J R
JR
Salli
U
U
Stormshak
F
F
D000818:Animals; D003008:Cloprostenol / Q000494:pharmacology; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D008183:Luteal Phase / Q000502:physiology*; D015735:Mifepristone / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism; D010121:Oxytocin / Q000097:blood / Q000378:metabolism*; D011374:Progesterone / Q000037:antagonists & inhibitors* / Q000097:blood; D011897:Random Allocation; D012756:Sheep
D006727:Hormone Antagonists; D015735:Mifepristone; D003008:Cloprostenol; D011374:Progesterone; D010121:Oxytocin